Yelena Krijanovski, M.D. Internal Medicine - Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 2702 Low Ct, Fairfield, CA 94534 Phone: 707-427-4900 Fax: 707-436-2509 |
Dr. Jonathan D Lopez, MD Internal Medicine - Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 1860 Pennsylvania Ave, Suite 230, Fairfield, CA 94533 Phone: 707-646-4000 Fax: 707-646-4004 |
News Archive
Inovio Biomedical Corporation, a leader in DNA vaccine design, development and delivery, announced today that it has expanded its existing license agreement with the University of Pennsylvania, adding exclusive worldwide licenses for technology and intellectual property for novel DNA vaccines against pandemic influenza, Chikungunya, and foot-and-mouth disease.
Around 600,000 Austrians suffer from diabetes. This condition is frequently associated with serious retinal disorders. Along with age-related macular degeneration, diabetic retinal degeneration is one of the most common causes of blindness. The Department of Ophthalmology and Optometry at MedUni Vienna was chosen by the European Society of Retina Specialists (EURETINA) to coordinate the development of up-to-date treatment and diagnostic guidelines.
Advocates of reauthorizing and expanding SCHIP "are warily training their eyes on next year with a mix of anticipation and anxiety" as it seems unlikely that there will be another vote on the legislation during the current congressional session, CongressDaily reports (Edney, CongressDaily, 9/15).
In response to today's vote by Congress to legislation that provides a 10-month delay to Medicare physician reimbursement cuts, freezing current rates and averting a 27.4 percent cut, the American Urological Association (AUA) issued the following statement.
Kineta, Inc. announced today its next generation antiviral program has received a 2.8 million dollar grant from the National Institute of Allergy and Infectious Disease, a part of the National Institutes of Health (NIH). Awarded under the Small Business Innovation Research (SBIR) program, the prestigious phase two grant will provide on-going support for Kineta's work on a new class of antiviral drugs targeting an array of global, deadly viruses.
› Verified 6 days ago